Trial Profile
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary) ; Albumin human
- Indications Septic shock; Staphylococcal infections; Streptococcal infections
- Focus Therapeutic Use
- Acronyms IGHN2
- 28 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment as no EC approval obtained.
- 18 Dec 2019 Planned End Date changed from 1 Apr 2022 to 1 Sep 2024.
- 18 Dec 2019 Planned primary completion date changed from 1 Apr 2022 to 1 Sep 2024.